Artículos por temáticas

Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.

Stanek LM, Yang W, Angus S, Sardi PS, Hayden MR, Hung GH, Bennett CF, Cheng SH, Shihabuddin LS.

J Huntingtons Dis. 2013;2(2):217-28. doi: 10.3233/JHD-130057.

Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease.

Laprairie RB, Kelly ME, Denovan-Wright EM.

Neuropharmacology. 2013 Sep;72:47-57. doi: 10.1016/j.neuropharm.2013.04.006.

Huntington's disease: easing the NMDAR traffic jam.

Daggett A, Yang XW.

Nat Med. 2013 Aug;19(8):971-3. doi: 10.1038/nm.3283. No abstract available.

Microtransplantation of whole ganglionic eminence cells ameliorates motor deficit, enlarges the volume of grafts, and prolongs survival in a rat model of Huntington's disease.

Zhu M, Shu K, Wang H, Li X, Xiao Q, Chan W, Emmanuel B, Jiang W, Lei T.

J Neurosci Res. 2013 Dec;91(12):1563-71. doi: 10.1002/jnr.23282.

Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models.

Cepeda C, Galvan L, Holley SM, Rao SP, André VM, Botelho EP, Chen JY, Watson JB, Deisseroth K, Levine MS.

J Neurosci. 2013 Apr 24;33(17):7393-406. doi: 10.1523/JNEUROSCI.2137-12.2013.

The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling.

Moreira Sousa C, McGuire JR, Thion MS, Gentien D, de la Grange P, Tezenas du Montcel S, Vincent-Salomon A, Durr A, Humbert S.

EMBO Mol Med. 2013 Feb;5(2):309-25. doi: 10.1002/emmm.201201546.

Commentary for Delayed onset of progressive chorea after acute basal ganglia injury"."

Walker RH.

Mov Disord. 2013 May;28(5):587-8. doi: 10.1002/mds.25481. No abstract available.

Longitudinal transcriptomic dysregulation in the peripheral blood of transgenic Huntington's disease monkeys.

Kocerha J, Liu Y, Willoughby D, Chidamparam K, Benito J, Nelson K, Xu Y, Chi T, Engelhardt H, Moran S, Yang SH, Li SH, Li XJ, Larkin K, Neumann A, Banta H, Yang JJ, Chan AW.

BMC Neurosci. 2013 Aug 17;14:88. doi: 10.1186/1471-2202-14-88.

Diffusion-weighted imaging in Sydenham's chorea.

Gumus H, Gumus G, Per H, Yikilmaz A, Canpolat M, Poyrazoglu G, Narin N.

Childs Nerv Syst. 2013 Jan;29(1):125-30. doi: 10.1007/s00381-012-1898-2.

Hope, humanity, and Huntington's disease in Latin America.

Burton A.

Lancet Neurol. 2013 Feb;12(2):133-4. doi: 10.1016/S1474-4422(13)70006-1. No abstract available.

Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.

Edlinger M, Seppi K, Fleischhacker W, Hofer A.

Int Clin Psychopharmacol. 2013 Jul;28(4):214-6. doi: 10.1097/YIC.0b013e328361e145.

Default-mode network changes in Huntington's disease: an integrated MRI study of functional connectivity and morphometry.

Quarantelli M, Salvatore E, Giorgio SM, Filla A, Cervo A, Russo CV, Cocozza S, Massarelli M, Brunetti A, De Michele G.

PLoS One. 2013 Aug 19;8(8):e72159. doi: 10.1371/journal.pone.0072159.

Attenuation of Rhes activity significantly delays the appearance of behavioral symptoms in a mouse model of Huntington's disease.

Baiamonte BA, Lee FA, Brewer ST, Spano D, LaHoste GJ.

PLoS One. 2013;8(1):e53606. doi: 10.1371/journal.pone.0053606.

Huntington's disease: the road to progress.

Walker FO.

Lancet Neurol. 2013 Jul;12(7):624-5. doi: 10.1016/S1474-4422(13)70105-4. No abstract available.

Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine.

Ribeiro M, Silva AC, Rodrigues J, Naia L, Rego AC.

Toxicol Sci. 2013 Dec;136(2):487-99. doi: 10.1093/toxsci/kft199.